(Q34591301)

3 August 2017

1 reference

title

Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy (English)

1 reference

3 August 2017

Mary Ann Ramirez

1

1 reference

3 August 2017

Nancy L Borja

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

3 August 2017

1 reference

3 August 2017

volume

28

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

646-655

1 reference

3 August 2017

cites work

Diabetic neuropathies

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.646

Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.646

Aldose reductase structures: implications for mechanism and inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.646

Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.646

Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.646

Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.646

Clinical potential of aldose reductase inhibitors in diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.646

Mechanisms of inhibitory activity of the aldose reductase inhibitor, epalrestat, on high glucose-mediated endothelial injury: neutrophil-endothelial cell adhesion and surface expression of endothelial adhesion molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.646

Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.646

Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.646

Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.646

Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.646

Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.646

Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.646

Osmotic Changes caused by the Accumulation of Dulcitol in the Lenses of Rats fed with Galactose

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.646

A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complications Trial (ADCT)

21 January 2018

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.1016/J.DIABRES.2007.01.069

Identifiers

DOI

10.1592/PHCO.28.5.646

1 reference

3 August 2017

1 reference